Full-Time

Global Trade Specialist

Import/Export

Resmed

Resmed

5,001-10,000 employees

Cloud-connected medical devices and software platforms

Compensation Overview

$85k - $127k/yr

Calabasas, CA, USA

Remote

Remote within United States; West Coast time zone alignment.

Bachelor's

Category
Operations & Logistics (1)
Required Skills
Tableau
Confluence

Get referred to Resmed

See people who can refer or advise you

Requirements
  • Bachelor’s degree in International Business, Supply Chain Management or related field
  • 5–8+ years of experience in trade compliance and import/export operations, preferably in medical devices
  • Fluency in English; proficiency in Spanish is a plus is not included here as it is in Desirable
  • Expertise in HTSUS, 19CFR, Canada Customs Act, Export Administration Regulations, customs clearance requirements for medical devices (e.g., classification, FDA AofC, origin), FTA use, C-TPAT and Incoterms® 2020
  • Expertise in implementing global trade compliance and controls, recordkeeping, import/export operational controls, supply chain security programs, continuous improvement methodologies, and the ability to manage compliance initiatives, audits, risk assessments, and cross-functional trade enablement activities
  • Digital & analytics tools: Experience using collaboration, documentation, and analytics platforms (e.g., Confluence, Tableau) to support trade data analysis, reporting, and data-driven decisions
  • Experience working with: ERP, GTM, national customs systems (e.g., ACE, CARM)
  • Advanced knowledge of tariff classification (HS codes), Country of Origin and export controls
  • Skilled in trade compliance, risk mitigation, audit preparedness, and root-cause investigations
  • Strategic mindset: able to develop and enforce trade policies and support trade facilitation into new markets
Responsibilities
  • Lead, manage and act as the subject matter expert on import/export compliance, ensuring adherence to customs regulations, tariff classifications, origin rules, valuation, international manufacturing and duty exclusion programs
  • Prepare and maintain import/export and Supply Chain Security internal controls, procedures, guidelines and audit materials
  • Serve as first-line intake for trade compliance and enablement requests, validating completeness, scope, and viability, and preparing clear dossiers for leadership review
  • Research and analyze regional trade regulations to determine their relevance and impact on the operation, supporting proactive compliance and strategic alignment
  • Monitor and interpret regulatory and customs changes across regions and global trading partners
  • Maintain trade compliance documentation and databases including customs clearance records, Certificates of Origin, Licenses, technical files and Harmonized Tariff Codes
  • Develop and implement GTM projects and continuous improvement initiatives
  • Support import/export, C-TPAT audits and investigations; prepare compliance and performance reports and risk assessments
  • Assist leader on tasks, special projects and act as GTM delegate, as needed
Desired Qualifications
  • Spanish language proficiency
  • CHB license
  • Travel: as needed

ResMed creates cloud-connected medical devices and software platforms to treat and manage sleep apnea, COPD, and other chronic diseases. Its devices (like sleep therapy gear) collect patient data and deliver therapy, while connected software platforms enable remote monitoring, coaching, and caregiver support. The company sells medical devices and offers software subscriptions, generating revenue from product sales and ongoing service fees. Unlike some competitors, ResMed combines hardware with cloud-based analytics and a broad ecosystem that supports patients, healthcare professionals, and caregivers across more than 120 countries. Its goal is to improve patient care and quality of life while reducing hospital visits and overall healthcare costs.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1989

Get referred to Resmed

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 revenue rose 10% and free cash flow reached $1.6 billion.
  • Frazier's July 7, 2026 MatrixCare acquisition sharpens ResMed around higher-growth core businesses.
  • The May 19, 2026 Oura deal expands screening, referrals, and downstream device demand.

What critics are saying

  • FDA classified Astral 100/150 recall Class I on July 31, 2026; sales stop.
  • Fiscal 2027 revenue guidance of $5.75 billion-$5.85 billion missed Wall Street on August 7, 2026.
  • Zepbound, Apple Watch sleep detection, and Philips reentry threaten ResMed's sleep franchise by 2027.

What makes Resmed unique

  • ResMed sells connected devices plus recurring software, creating durable, high-margin service revenue.
  • Its May 19, 2026 Oura partnership funnels wearables users into clinical sleep care.
  • ResMed keeps leadership in sleep and home breathing care across 140 countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

Parental Leave

401(k) Retirement Plan

Employee Assistance Program (EAP)

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

6%

2 year growth

6%
Yahoo Finance
Aug 10th, 2026
ResMed Q2 revenue up 8.6% to $1.46B but margins fall amid R&D and supply chain costs

ResMed reported second-quarter revenue of $1.46 billion, meeting analyst expectations with 8.6% year-on-year growth. The medical device company's adjusted earnings per share of $2.95 beat estimates by 2%. Despite steady revenue growth, ResMed's operating margin declined to 30.7% from 33.7% in the prior year period. Management attributed the compression to higher R&D and supply chain costs amid inflation. The company also recorded a $42 million charge related to a field safety action on its Astral devices. Chief executive Mick Farrell highlighted ongoing investments in innovation and supply chain efficiency. Looking ahead, ResMed expects modest price increases and productivity initiatives to offset inflation in electronic components and freight whilst expanding its digital health ecosystem.

Yahoo Finance
Aug 7th, 2026
ResMed shares fall 6% as ventilator recall and cost pressures drag fiscal 2027 revenue forecast below expectations

ResMed shares fell about 6% on Friday after the medical device company forecast fiscal 2027 revenue of $5.75 billion to $5.85 billion, below analysts' expectations of $5.92 billion. The weak guidance follows ResMed's decision to suspend sales of its Astral ventilators after an FDA recall linked to five serious injuries. The company expects a $75 million impact from the suspension as it redirects electronic components to repair existing devices. ResMed also faces competitive pressure from Eli Lilly's weight-loss drug Zepbound, approved in 2024 to treat obstructive sleep apnea. The company plans price increases to offset rising costs for electronic components and freight. Despite the weak outlook, ResMed beat fourth-quarter profit estimates, reporting adjusted earnings of $2.95 per share versus expectations of $2.89. Revenue rose 9% to $1.46 billion.

Midwest Communications
Aug 7th, 2026
ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat.

ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat. By Thomson Reuters Aug 7, 2026 | 11:00 AM By Padmanabhan Ananthan and Kunal Das Aug 7 (Reuters) - Shares of ResMed dropped about 6% in morning trade on Friday after the medtech company forecast fiscal 2027 revenue below Wall Street expectations, impacted by suspended ventilator sales and cost pressures. ResMed said it would suspend sales of its Astral ventilators, used by patients who require acute or long-term life-support, following a device correction and FDA recall tied to five serious injuries last week. The fresh guidance assumes no sales of Astral ventilators during fiscal 2027 and factors in an expected $75 million impact due to the suspension, as the company redirects scarce electronic components to support repairs and servicing of existing devices. ResMed said it has not yet decided whether Astral sales will resume in fiscal 2028. The company now expects fiscal 2027 revenue of $5.75 billion to $5.85 billion, below analysts' expectations of $5.92 billion, according to data compiled by LSEG. Emerging competitive and ongoing cost pressures also limit its growth outlook, Baird analyst David Rescott said. ResMed, which makes devices to manage sleep apnea, among other medical equipment, plans to increase prices during fiscal 2027 as rising costs for electronic components and freight pressure its margins. "We can no longer offset inflation with productivity alone," CFO Aaron Bloomer said on a call with analysts. ResMed's sleep apnea devices face competition from Eli Lilly's weight-loss drug Zepbound, which was approved by the FDA in 2024 to treat obstructive sleep apnea. While the condition can affect anyone, it is more common in people who are overweight or obese, according to the health regulator. But Morningstar analysts said the Apple Watch's ability to identify possible sleep apnea cases could drive more diagnoses and treatment, which could help counter the weight-loss-drug threat to ResMed's devices. Sleep apnea devices are still the standard of care on the market and widely used. ResMed reported fourth-quarter adjusted profit of $2.95 per share, topping estimates of $2.89, while revenue rose 9% to $1.46 billion, in line with expectations. (Reporting by Kunal Das and Padmanabhan Ananthan in Bengaluru; Editing by Jonathan Ananda)

MD+DI
Aug 4th, 2026
Is ResMed looking at price bumps?

Is ResMed looking at price bumps? A home health medical equipment company called out a $30M impact from a large manufacturer. ResMed is suspected of being the manufacturer in question. August 4, 2026 AdaptHealth, a large public home medical equipment company, called out a $30 million impact in the second half of the year from a manufacturer price hike. One analyst thinks that the manufacturer could be ResMed. "Management did not specify the business category of the price increase but did note that it was from one of its largest manufacturers," Mike Matson, a Needham & Co. medtech analyst, wrote in a report Tuesday. "...Although MD+DI has no way of knowing for sure, there are reasons to believe that ResMed could be the manufacturer that [AdaptHealth] is referring to. MD+DI reached out to ResMed for comment on the analyst's speculation and will update this article when the company responds. The manufacturer in question notified AdaptHealth at the end of June that it was terminating its contract and imposing an immediate price increase on July 1. Matson cited three reasons for speculating that ResMed is the manufacturer raising its prices on AdaptHealth. * ResMed's fiscal year ended on June 30 and coincides with the price increase. * Sleep is AdaptHealth's largest category and accounts for 52% of its overall revenue. * ResMed has a near-monopoly in flow generators since Philips exited the market a few years ago. "If the price increase was in fact from [ResMed], it remains to be seen if this was a one-off move with a single customer or wider price increase across most or all of its customers," Matson writes. "We think an abrupt widespread pricing increase could be a sign of margin pressures at [ResMed]. On one hand, any pricing increase from [ResMed] could be positive since it might offset margin pressures in FY27. On the other hand, we think [ResMed] risks losing share (to React Health, its primary flow generator competitor) and angering its customers in advance of [Philips] eventual reentry into the U.S. flow generator market." ResMed is expected to report its fiscal fourth-quarter results Thursday afternoon. AdaptHealth has reshaped its business around its core sleep, respiratory, and supporting home medical equipment business over the last two years, Suzanne Foster, the company's CEO and director, said during AdaptHealth's Q2 earnings call Tuesday. Given the company is in active negotiation with the manufacturer in question for a better price, Foster declined to say which business segment the price hike is hitting. "Obviously, mid-year, we do not, as a company, have the opportunity to pass through price," Foster said. "We are hopeful that we'll be able to resolve this." In the meantime, she said, the actions the company would have to take include things like looking at supplier mix and profitability of those products within the mix to offset the price increase. If the manufacturer doing the price hike is ResMed, the news would come as ResMed is dealing with a serious problem with some of its ventilators. The company recently alerted customers that a faulty component in certain Astral 100 and Astral 150 ventilators could cause the devices to suddenly stop working. This is a potentially life-threatening scenario for patients who depend on them to breathe. Want more MD+DI in your search results?

Yahoo Finance
Aug 3rd, 2026
ResMed's 31.7% cash flow margin leads watchlist as Hasbro and Enphase face headwinds

ResMed develops cloud-connected medical devices and software solutions for sleep apnea, COPD, and other respiratory disorders. The company reported a trailing 12-month free cash flow margin of 31.7%. ResMed demonstrated strong financial performance over recent years. The company achieved constant currency growth averaging 9.1% over the past two years, showing global expansion capability regardless of macroeconomic conditions. Earnings per share increased by 15.2% annually over the last five years, outpacing revenue gains. The company's free cash flow margin grew by 21.4 percentage points during the same period. Meanwhile, investment firm StockStory identified Hasbro and Enphase as companies facing challenges despite producing cash. Hasbro reported annual sales declines of 3.5% over five years, whilst Enphase experienced declining unit sales and decreasing free cash flow margins.